Press Releases

Investors  /  Press Releases

All Press Releases

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

Palisade Bio Announces 1-for-15 Reverse Stock Split

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Palisade Bio Provides Corporate Update and Reiterates Guidance

Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Palisade Bio Reports Second Quarter 2023 Financial Results

Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

Palisade Bio Reports First Quarter 2023 Financial Results

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

Palisade Bio Promotes Robert McRae to Chief Operating Officer

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event

Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video

Palisade Bio Announces Reverse Stock Split

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Palisade Bio Announces Executive Leadership Transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148

Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health – Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio to Present at the 2022 BIO International Convention

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

Palisade Bio Announces $2.0 Million Registered Direct Offering

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event

Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference

Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase

Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus

Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations

Palisade Bio Reports Third Quarter Financial Results

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dysfunction

Leading BioSciences Closes Merger with Seneca Biopharma and Set to Begin Trading on Nasdaq as PALI

Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study

Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtual Special Meeting on April 23, 2021 and Upcoming Milestones Following Planned Close of Merger

Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021

Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.

Leading BioSciences Encourages Seneca Biopharma Stockholders to Vote “FOR” Proposed Merger

Seneca Special Meeting Q&A

Leading BioSciences to Present at the H.C. Wainwright Global Life Sciences Conference

Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements

Seneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic Stroke

Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular Surgery

Leading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery Study

Leading BioSciences and Seneca Biopharma Announce Merger

Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic

Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study

Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients

Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery

Leading BioSciences to Present at Planet MicroCap Showcase 2019

Leading BioSciences to Present at Biotech Showcase 2019

Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors

Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery

Email Alerts
Email Alerts
Contact IR
Contact IR
Search
Search